Cancers, Vol. 16, Pages 670: Bortezomib in Combination with Physachenolide C Reduces the Tumorigenic Properties of KRASmut/P53mut Lung Cancer Cells by Inhibiting c-FLIP

Conclusion: These findings demonstrate that PCC sensitizes cancer cells to bortezomib, potentially improving the antitumor effects against KRASmut/P53mut lung cancer cells, with an enhanced efficacy of combination treatments without causing significant side effects.

Source: Cancers - February 4, 2024 Category: Cancer & Oncology Authors: Thanigaivelan Kanagasabai Zerick Dunbar Salvador Gonz ález Ochoa Tonie Farris Sivanesan Dhandayuthapani E. M. Kithsiri Wijeratne A. A. Leslie Gunatilaka Anil Shanker Tags: Article Source Type: research